Delving into the Latest Updates on Ramipril with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Acuvil, Carasel, Delix

+ [19]

Target

ACE

Action

inhibitors

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesUrogenital Diseases

Active Indication

Acute myocardial infarctionEssential HypertensionNephrosis+ [6]

Inactive Indication

AlbuminuriaAngina PectorisAtrial Fibrillation+ [10]

Originator Organization

Pfizer Inc.

Active Organization

Aventis Pharma Deutschland GmbH

Rosemont Pharmaceuticals Ltd.

Libbs Farmacêutica Ltda.

Inactive Organization

Sanofi

Aventis Pharmaceuticals, Inc.

King Pharmaceuticals LLC

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (28 Jan 1991),

Heart FailureHypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H32N2O5

InChIKeyHDACQVRGBOVJII-JBDAPHQKSA-N

CAS Registry87333-19-5

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)

Start Date06 Jan 2025

Sponsor / Collaborator

Region Västra Götaland

CTIS2024-514456-32-00

/ Not yet recruitingPhase 1

A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.

Start Date09 Sep 2024

Sponsor / Collaborator-

CTR20241890

/ CompletedNot Applicable

雷米普利片（5 mg）随机、开放、两周期、两交叉单次给药空腹/餐后状态下在健康受试者中的生物等效性试验

[Translation] A randomized, open-label, two-period, two-crossover single-dose bioequivalence study of ramipril tablets (5 mg) in healthy volunteers under fasting/fed conditions

主要研究目的：在健康男性与女性受试者中于空腹/餐后条件下，评价受试制剂雷米普利片（规格：5 mg，生产商：浙江华海制药科技有限公司）和Sanofi Belgium为持证商的参比制剂雷米普利片（Tritace，规格：5 mg）的生物等效性。次要研究目的：观察受试制剂雷米普利片与参比制剂雷米普利片（Tritace）在健康受试者中的安全性。

[Translation]

Primary study objective: To evaluate the bioequivalence of the test preparation Ramipril Tablets (Specification: 5 mg, Manufacturer: Zhejiang Huahai Pharmaceutical Technology Co., Ltd.) and the reference preparation Ramipril Tablets (Tritace, Specification: 5 mg) licensed by Sanofi Belgium in healthy male and female subjects under fasting/postprandial conditions. Secondary study objective: To observe the safety of the test preparation Ramipril Tablets and the reference preparation Ramipril Tablets (Tritace) in healthy subjects.

Start Date20 Jun 2024

Sponsor / Collaborator

Zhejiang Huahai Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Ramipril

Login to view more data

100 Translational Medicine associated with Ramipril

Login to view more data

100 Patents (Medical) associated with Ramipril

Login to view more data

3,814

Literatures (Medical) associated with Ramipril

31 Dec 2025·BLOOD PRESSURE

Malignant hypertension, and if it was scleroderma? Lessons from two cases

Article

Author: Laamech, Réda ; Giovannini, Diane ; Cellot, Etienne ; Jost, Sandra ; Franko, Benoit

Inroduction : Scleroderma Renal Crisis (SRC) is characterised by acute hypertension, haemolytic anaemia (HA), and acute kidney injury (AKI). Often presenting as the first manifestation of scleroderma, it is frequently mistaken for malignant hypertension (MHT). Rapid recognition and differentiation of SRC from other hypertensive emergencies are essential for improving patient outcomes.We present two clinical cases that illustrate the diagnostic challenges of SRC in the context of MHT.Case 1: A 53-year-old man presented with severe hypertension (238/127 mmHg) and AKI (creatinine 390 μmol/L). He was diagnosed MHT due to the presence of grade III hypertensive retinopathy and HA. . However, a urine dipstick test detected haematuria, leading to further immune testing and, a renal biopsy, which confirmed SRC. Treatment with high-dose ramipril led to a sustained recovery of kidney function, 221 μmol/L after five years).Case 2: A 52-year-old man presented with chest pain, severe hypertension (253/132 mmHg), and AKI (creatinine 183 μmol/L). Initially managed as MHT, his kidney function worsened, prompting further investigation, which revealed haematuria and positive anti-nuclear antibodies. A renal biopsy confirmed SRC. High-dose ramipril was reintroduced, leading to partial kidney function recovery (creatinine 218 μmol/L after five years).Key findings : These cases underscore the importance of early detection of hematuria and autoimmune markers to expedite diagnosis of SRC in case of MHT. When SRC is suspected, high-dose angiotensin-converting enzyme inhibitors (ACEi) should be initiated immediately, even before biopsy confirmation and continued despite initial kidney function decline. Early intervention is crucial for optimising kidney outcomes and achieving effective blood pressure control.

01 Dec 2025·AMERICAN JOURNAL OF CARDIOLOGY

Differences in Characteristics and Clinical Outcomes According to Age in Patients Following High-Risk Myocardial Infarction: Insights from PARADISE-MI

Article

Author: Rouleau, Jean Lucien ; Solomon, Scott David ; Køber, Lars ; Merkely, Bela ; Amir, Offer ; Landmesser, Ulf ; DePasquale, Carmine ; Maggioni, Aldo Pietro ; Senni, Michele ; McMurray, John Jv ; Claggett, Brian Lee ; Pfeffer, Marc Alan ; Opolski, Grzegorz ; Claeys, Marc J ; Jering, Karola Simone ; Lewis, Eldrin Foster ; Granger, Christopher Bull ; Cikes, Maja ; van der Meer, Peter

The prevalence of coronary heart disease is increasing in an aging population. A better understanding of how risk profiles and outcomes differ by age may allow for targeted treatment and prevention strategies. PARADISE-MI randomized 5661 adults without prior heart failure (HF) to sacubitril/valsartan versus ramipril within 0.5 to 7 days of a MI complicated by pulmonary congestion and/or LVEF ≤40%. Associations between age and clinical outcomes were analyzed using Cox models, adjusted for potential confounders. Mean age was 63.7 ± 11.5 years. Patients aged ≥75 years (n = 1051, 18.6%) were more often women, had more atrial fibrillation and lower eGFR. They more commonly presented with non-ST-segment elevation MI and were less likely to receive primary reperfusion and guideline-based medical therapies. Age was associated with all-cause death (HR 1.54 per 10-year increase; 95% CI, 1.41 to 1.68) and was more strongly associated with non-CV death (HR 2.09; 95% CI, 1.70 to 2.56) than with CV death (HR 1.43; 95% CI, 1.29 to 1.57). Age was associated with incident HF (HR 1.37; 95% CI, 1.25 to 1.49) and stroke (HR 1.31; 95% CI, 1.11 to 1.54). These risk relationships were similar after multivariable adjustment. The treatment effect of sacubitril/valsartan versus ramipril was not significantly modified by age (p-interaction = 0.19) and tolerability did not differ by treatment arm. In conclusion, the heightened risk of death, HF and stroke after MI with advancing age was not explained by differences in clinical characteristics. Older patients may require closer surveillance and more guidelines-based therapies after MI to mitigate the elevated risk of death and HF.

01 Dec 2025·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Aquatic photochemistry and transformations of multiclass emerging organic contaminants in environmental water matrices

Author: Bajt, Oliver ; Prosen, Helena ; Kravos, Aleksander

This study shows a comprehensive assessment of the photodegradation of 18 multiclass contaminants of emerging concern (CECs) in simulated river and marine aquatic compartments.Degradation trends, mineralization, and defluorination of the target CECs were monitored in model matrixes, artificial and real seawater, with and without aeration.Each model matrix contained a natural abiotic factor of interest, i.e., chloride, nitrate, humic acid, lignosulfonate, and iron, all naturally present in surface water.Transformation pathways were investigated by UHPLC-MS/MS and for the identified transformation products (TPs), their ecotoxicities were predicted in silico.Only 8 out of 18 selected CECs were found to be significantly photolabile, especially rosuvastatin.Direct photolysis was their primary degradation route, while abiotic factors either accelerated or suppressed the degradation depending on the type of CEC.Real and artificial seawater mostly acted inhibitory.Oxygen aeration mostly accelerated degradation showing the effect of singlet oxygen.Low mineralization and defluorination were in most cases linked to the formation of stable and relatively more toxic TPs, which were characteristic for rosuvastatin.Main identified TPs were screened in real river water and seawater (North Adriatic Sea water basin, Slovenia, Europe).Rosuvastatin′s TP ROS-349 was detected with a high confidence level for the first time, which may raise environmental concerns.Overall, advanced assessment of aquatic photochem. is achieved by using low concentrations, mixtures of multiclass CECs, UV light above 300 nm, more realistic matrixes, as well as by identifying, ranking, and analyzing the TPs in actual aquatic environment.

19

News (Medical) associated with Ramipril

31 Jul 2025

·www.einpresswire.com

Rosemont Pharmaceuticals announces FDA Approval of VOSTALLY®(ramipril) Oral Solution for treatment of adult hypertension

Rosemont Pharmaceuticals announces FDA Approval of VOSTALLY® (ramipril) Oral Solution for the treatment of hypertension in adults to lower blood pressure. GREENVILLE, MS, UNITED STATES, July 31, 2025 / EINPresswire.com / -- Rosemont Pharmaceuticals, Inc. announced that on July 23, 2025, the U.S. Food and Drug Administration (FDA) has approved VOSTALLY (ramipril) Oral Solution, an angiotensin converting enzyme (ACE) inhibitor that offers once-daily dosing in an oral liquid form for patients who have difficulty swallowing. VOSTALLY is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Additionally, in patients 55 years or older at high risk of developing a major cardiovascular event, VOSTALLY is indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Also, in adult patients with post-myocardial infarction heart failure, VOSTALLY is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure. VOSTALLY is contraindicated in patients with a history of angioedema or hypersensitivity to this product or any other ACE inhibitor and in patients with hereditary or idiopathic angioedema. VOSTALLY is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer VOSTALLY within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor. Do not co-administer VOSTALLY with aliskiren in patients with diabetes. “We are proud to bring VOSTALLY to physicians to treat patients who may benefit from an ACE inhibitor but whose difficulty swallowing a tablet creates a barrier to this kind of therapy,” said Jeff Bryant, President of Sabal Therapeutics, a Rosemont Company. “This oral liquid form of ramipril provides physicians with another option for treating patients.” “This FDA approval of VOSTALLY marks an important milestone in expanding treatment options for patients who have difficulty swallowing traditional tablets or capsules,” continued Mr. Bryant. “We are proud to support Rosemont’s commitment to delivering high-quality oral liquid medicines to the U.S. market and believe VOSTALLY will provide a meaningful benefit to both patients and healthcare providers and payors.” VOSTALLY will be available later this year. Full Prescribing Information, including boxed warning and safety profile, is available at www.RosemontPharmaceuticals.com . About Rosemont Pharmaceuticals Rosemont Pharmaceuticals is a U.K. headquartered pharmaceutical company specialized in the development and commercialization of oral liquid medicines. Rosemont was founded more than 50 years ago and sells over 130 liquid products in more than 27 markets. In July 2024, Rosemont announced the acquisition of Sabal Therapeutics, a U.S. based pharmaceutical company, specialized in liquid medicines, thereby expanding their footprint into the U.S. RMT-VOS-PR-001 07/2025 Wade Harper, Vice President, Commercial Officer Sabal Therapeutics, LLC wharper@sabalrx.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalAcquisition

24 Apr 2025

·www.fiercepharma.com

Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results

Lupin is no stranger to recalls, and has at times even had to suspend production of U.S.-bound drugs at its plants. Mumbai's Lupin has issued a voluntary recall of 2,724 bottles of the tricyclic antidepressant clomiPRAMINE hydrochloride, which is used to treat obsessive-compulsive disorder (OCD) by boosting serotonin activity in the brain.Lupin’s product pull covers 25-mg capsules of the drug in 100-count bottles. The suspect batch, which was distributed across the U.S., was set to expire at the end of June, according to a recent FDA enforcement report. The manufacturer formally kicked off the recall on April 10.According to the FDA’s report, Lupin said the drug—manufactured at the company’s Baltimore, Maryland, production site—failed to meet impurities and degradation specifications during an 18-month stability study.The recall ranks as Class II, which means the FDA figures there is a low chance the issue could cause serious injuries or death. Lupin is no stranger to recalls, and has at times even had to suspend production of U.S.-bound drugs at its plants.In late November, Lupin recalled more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due to the presence of an active pharmaceutical ingredient (API) that came from an unapproved vendor.Before that, the company in 2023 pulled two lots of birth control pills from U.S. shelves. The recall, which covered Tydemy tablets, also stemmed from out-of-specification stability testing results that led Lupin to fear the drugs might not be effective in preventing pregnancy.As for the manufacturing suspension at its troubled Tarapur facility in the Indian state of Maharashtra, the FDA in 2022 asked Lupin to alert it before resuming operations there with the intent to produce for the U.S. market. The restriction followed the receipt of a warning letter at that facility.Elsewhere, multiple other drugmakers have initiated recalls of their own in 2025.Glenmark pulled roughly 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine in early March, citing unacceptable levels of the possible carcinogen N-nitroso atomoxetine. Prior to that, ICU Medical in February recalled two lots of potassium chloride intravenous bags over labeling issues that could increase the chances of an accidental overdose. Potassium chloride solution is used to rapidly restore potassium levels in patients with hypokalemia.Meanwhile, Alvogen, Astellas Pharma and Endo have triggered 2025 recalls on pain meds, immunosuppressants and vasoconstrictors, respectively.

26 Nov 2024

·pharma.economictimes.indiatimes.com

Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA

New Delhi: Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA), stated that Dr Reddy's Laboratoties is also recalling a product in the US due to a manufacturing issue. Baltimore-based Lupin Pharmaceuticals Inc , a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the US health regulator said. The affected lot is manufactured at Lupin's Goa-based manufacturing facility, it stated. The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said. The US health regulator noted that the company is undertaking Class II voluntary recall due to "CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor." Lupin Pharmaceuticals Inc initiated the recall on October 23 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. In a separate listing, USFDA stated that a US-based unit of Dr Reddy's Laboratories is recalling 3,416 Made in India bottles of IBU (ibuprofen) 600 mg tablets in the US. Princeton (NJ) based Dr Reddy's Laboratories, Inc initiated the Class III recall due to "Failed Tablet/Capsule Specifications," USFDA said. The company initiated the voluntary recall on October 29. As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."

100 Deals associated with Ramipril

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00421	Ramipril	C09AA05	DB00178

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute myocardial infarction	China	Aventis Pharma Deutschland GmbH	23 Jul 2004
Essential Hypertension	China	Aventis Pharma Deutschland GmbH	23 Jul 2004
Nephrosis	China	Aventis Pharma Deutschland GmbH	23 Jul 2004
Stroke	China	Aventis Pharma Deutschland GmbH	23 Jul 2004
Cardiovascular Diseases	Brazil	Libbs Farmacêutica Ltda.	09 Aug 1999
Kidney Diseases	Brazil	Libbs Farmacêutica Ltda.	09 Aug 1999
Myocardial Infarction	Brazil	Libbs Farmacêutica Ltda.	09 Aug 1999
Heart Failure	United States	King Pharmaceuticals LLC	28 Jan 1991
Hypertension	United States	King Pharmaceuticals LLC	28 Jan 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 3	France	Sanofi	01 Jul 2008
Atrial Flutter	Phase 3	France	Sanofi	01 Jul 2008
Glomerulonephritis, IGA	Phase 3	Hong Kong	Sanofi	01 Jul 2004
Angina Pectoris	Phase 3	-	Sanofi	01 Jun 2004
Rheumatoid Arthritis	Phase 3	-	Sanofi	01 Jun 2004
Kidney Failure, Chronic	Phase 3	Czechia	Aventis Pharmaceuticals, Inc.	01 Jan 1998
Kidney Failure, Chronic	Phase 3	France	Aventis Pharmaceuticals, Inc.	01 Jan 1998
Kidney Failure, Chronic	Phase 3	Germany	Aventis Pharmaceuticals, Inc.	01 Jan 1998
Kidney Failure, Chronic	Phase 3	Hungary	Aventis Pharmaceuticals, Inc.	01 Jan 1998
Kidney Failure, Chronic	Phase 3	Italy	Aventis Pharmaceuticals, Inc.	01 Jan 1998

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06104423 (ARTEMISIA, CTgov)	Phase 4	Hypertension	266	Nebivolol 5 mg+Ramipril 2.5/5/10 mg	qwqrppbdrv(asigigwwey) = fifluetgmc htcgfldrjy (ihvsrmeulo, xbfvnaxgnx - yzosvvipaq) View more	-	24 Apr 2025
NCT03475186 (WF-1801, SNO2024)	Phase 2	Glioblastoma	75	Ramipril	srsmzbmvuu(ijfvgopbbt) = spveqxcgcl ogpeakadui (udwmnbuziv, 38% - 100) View more	Negative	11 Nov 2024
NCT03201185 (RASTAVI, Pubmed \| J Am Heart Assoc) Manual	Phase 4	Heart Failure	186	Ramipril	vtzamikuzb(zhwdyliiob) = wkxfvxlcce vcpnhmkccn (pxxqpolxcz ) View more	Negative	18 Sep 2024
				Standard treatment	vtzamikuzb(zhwdyliiob) = ukjgyvjkjy vcpnhmkccn (pxxqpolxcz ) View more
NCT04366050 (RAMIC, CTgov)	Phase 2	COVID-19	160	Ramipril 2.5 MG Oral Capsule (Ramipril 2.5mg Orally Daily)	uysxobbgko = mhuetvbxam onynmfkgla (dstzpdocti, cygqabzxew - kvfbvnegwy) View more	-	28 Sep 2023
				Placebo oral capsule (Placebo)	uysxobbgko = poegwphixa onynmfkgla (dstzpdocti, swqltsnsda - uhvyfkebpx) View more
NCT02924727 (PARADISE-MI, ESC2023)	Phase 3	Acute myocardial infarction	-	Sacubitril/valsartan	swlkwkiwmp(uendktvqmt) = moayydlgeh iyauyjhqyp (pccqonuytm ) View more	-	23 May 2023
NCT03979976 (Pubmed \| J Clin Rheumatol)	Phase 2/3	Systemic Lupus Erythematosus	37	Ramipril 10 mg/d	czyulbgnuj(ayqgaaarir) = tgzacwthyx iekwxzslmr (rpwgqrqyxv )	Positive	03 Jun 2022
				Control group without ramipril	czyulbgnuj(ayqgaaarir) = mjsjzxnmeb iekwxzslmr (rpwgqrqyxv )
NCT03011775 (EFFORT, CTgov)	Phase 4	Insulin Resistance \| Coronary Artery Disease \| Atherosclerosis ... View more	43	Rosuvastatin Calcium 20 MG Oral Tablet+Bisoprolol Fumarate 2.5 MG Oral Tablet+Ramipril 5 MG+Isosorbide Dinitrate 10Mg Tablet+Pioglitazone 15 mg Tablet+Acetylsalicylic Acid 75Mg Tablet (Pioglitazone + Standard Care)	frqonjifuq = wmxvslxhyl vclicmlpww (vipnczefwf, rpezjpswgz - nrxveeozhs) View more	-	10 Mar 2022
				Rosuvastatin Calcium 20 MG Oral Tablet+Bisoprolol Fumarate 2.5 MG Oral Tablet+Ramipril 5 MG+Isosorbide Dinitrate 10Mg Tablet+Acetylsalicylic Acid 75Mg Tablet (Standard Care)	frqonjifuq = affyomojhy vclicmlpww (vipnczefwf, cjtxsmratt - dwayiqvsfh) View more
NCT04582097 (MO1008, ERA2021)	Phase 2/3	Maintenance asymmetric dimethyl arginine (ADMA)	135	Ramipril 2.5 mg	rwfaqnyyxb(kazcbqphtf) = No serious adverse events were reported in neither group qmsvjjxzns (uawlzmglqz )	Positive	29 May 2021
NCT00985322 (ARCADIA, Pubmed \| Clin J Am Soc Nephrol)	Phase 3	Maintenance	269	Ramipril	fttuedxavq(pyztmiptna) = Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinal malignancies on ramipril (four were fatal), compared with none in controls ltiktdnywe (sjenudeutu ) View more	Negative	29 Mar 2021
				Non-RAS inhibition therapy
NCT00980785 (SEAIRA, CTgov)	Phase 4	Alzheimer Disease \| Hypertension	14	Placebo (Placebo)	jochzbeija(daiqobchot) = xqkeztwogf qyjtvpoonk (obrddutetx, 78.7) View more	-	25 Aug 2020
				Ramipril (Active)	jochzbeija(daiqobchot) = dzpbujlfsl qyjtvpoonk (obrddutetx, 90.6) View more